OCT 28, 2020 7:00 AM PDT

Guiding pancreatic cancer therapy by individualized epigenetics

Sponsored by: Agilent
C.E. Credits: P.A.C.E. CE Florida CE
Speakers

Abstract
Date:  October 28, 2020
Time: 7:00am (PDT),  10:00am (EDT)
 
Although chemotherapy remains the mainstay of systemic therapy, a large number of cancer patients fail to respond to it. About half of surgically resected pancreatic ductal adenocarcinoma (PDAC) patients relapse within a year despite adjuvant chemotherapy. By investigating tumor-cell-intrinsic chromatin accessibility patterns of resected PDAC, we discovered a signature of 1092 chromatin loci displaying differential accessibility between patients with disease free survival (DFS) < 1 year and patients with DFS > 1 year. Based on this signature, we developed “ATAC-array” – the only microarray that reads chromatin accessibility – a convenient platform obviating the time and cost of Next Generation Sequencing. We also identified HNF1b, a transcription factor displaying differential nuclear localization between patients with short vs. long DFS. Combining these two simple methodologies, ATAC-array “Prognosis Score” and HNF1b nuclear localization, we have developed an algorithm which we call PancEpistemeDx, and stratified PDAC patients into prognostic groups with up to four-fold differences in DFS. Whether adverse patterns of chromatin accessibility might assist in the selection of PDAC patients for epigenetic “reprogramming” therapy remains to be determined, but our stratification provides a simple and clinically achievable prediction of favorable vs unfavorable epigenetic states in PDAC. Episteme Prognostics aims to 1) optimize PancEpistemeDx for routine clinical use and expand it to all stages of pancreatic cancer, and 2) develop companion diagnostics (CDx) for epigenetic drugs. We sit at the dawn of the epigenetic drug discovery era, the FDA has already approved 9 epigenetic drugs, and currently, 138 clinical trials on epigenetic drugs are registered by 31 different pharmaceutical companies. Our technology can support therapeutic decision-making in pancreatic cancer clinics, as well as can support clinical trials on epigenetic drug discovery for pharma companies.
 
Learning Objectives:
  • How epigenetics adds an important layer of information on top of genetic mutations to inform cancer research
  • How microarray analysis may reveal innovative approaches to deliver companion diagnostics in the future
  • How epigenetics may be used as a novel approach to drug discovery
 
For Research Use Only. Not for use in diagnostic procedures.
 
 
Webinars will be available for unlimited on-demand viewing after live event.
 
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
MAR 16, 2022 8:00 AM PDT
C.E. CREDITS
MAR 16, 2022 8:00 AM PDT
Date: March 16, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CET) Handling of potent and/or hazardous substances is commonplace in sev.....
DEC 01, 2021 7:00 AM PST
C.E. CREDITS
DEC 01, 2021 7:00 AM PST
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
APR 28, 2022 8:00 AM PDT
APR 28, 2022 8:00 AM PDT
Date: April 28, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Human pluripotent stem cells (PSCs) and their derivatives hold great potentials in...
DEC 09, 2021 11:00 AM PST
C.E. CREDITS
DEC 09, 2021 11:00 AM PST
Date: December 09, 2021 Time: 11:00am (PDT), 2:00pm (EDT) The burden of antimicrobial resistance (AMR) has been acknowledged worldwide by leading health institutes. Besides the need for new...
NOV 30, 2021 10:00 AM PST
C.E. CREDITS
NOV 30, 2021 10:00 AM PST
Date: November 30, 2021 Time: 10:00am (PDT), 1:00pm (EDT) The prevalence of thyroid disease worldwide has served as a catalyst for healthcare providers to study various tools and methods to...
Loading Comments...
Show Resources